GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients With Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and Economic Outcomes,
June 06, 2024
June 06, 2024
MARLBOROUGH, Massachusetts, June 6 (TNSres) -- GE HealthCare issued the following news release:
* * *
* Adding a PET/CT scan with [18F]FES, a breast oncology PET tracer, may increase the accuracy of knowing the estrogen receptor (ER) status. This is notable when a tumor sample cannot be obtained, or the risk of a biopsy-related complication is high.
* Increased diagnostic accuracy may help clinicians select more effective treatments and decrease the rate of . . .
* * *
* Adding a PET/CT scan with [18F]FES, a breast oncology PET tracer, may increase the accuracy of knowing the estrogen receptor (ER) status. This is notable when a tumor sample cannot be obtained, or the risk of a biopsy-related complication is high.
* Increased diagnostic accuracy may help clinicians select more effective treatments and decrease the rate of . . .